0001560293 1 2026-06-20 2026-06-20 0001560293 2 2026-06-20 2026-06-20 0001560293 3 2026-06-20 2026-06-20 0001560293 4 2026-06-20 2026-06-20 0001560293 5 2026-06-20 2026-06-20 0001560293 6 2026-06-20 2026-06-20 0001560293 7 2026-06-20 2026-06-20 0001560293 2026-06-20 2026-06-20 iso4217:USD pure S-1 EX-FILING FEES 0001560293 N/A N/A S-1 Tenon Medical, Inc. false Equity Common stock, par value $0.001 per share true 4025000.00 0.0001381 555.85 false Equity Pre-funded warrants to purchase common stock, $0.001 par value per share true 0.0001381 0.00 false Equity Common stock, $0.001 par value per share, underlying the pre-funded warrants true 0.00 0.0001381 0.00 false Equity Common stock purchase warrants to purchase common stock true 0.0001381 0.00 false Equity Common stock, par value $0.001 per share, underlying Common stock purchase warrants true 6037500.00 0.0001381 833.78 false Equity Underwriter Warrants to purchase common stock true 0.0001381 0.00 false Equity Common stock, par value $0.0001 per share, underlying underwriter warrants true 144900.00 0.0001381 20.01 10207400.00 1409.64 0.00 0.00 1409.64 Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), the registrant is also registering an indeterminate number of additional shares of Common Stock that may become issuable as a result of any stock dividend, stock split, recapitalization or other similar transaction, and the shares of Common Stock set forth in this table shall be adjusted to include such shares, as applicable. Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(o) under the Securities Act. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), the registrant is also registering an indeterminate number of additional shares of Common Stock that may become issuable as a result of any stock dividend, stock split, recapitalization or other similar transaction, and the shares of Common Stock set forth in this table shall be adjusted to include such shares, as applicable. Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(o) under the Securities Act. No separate fee is required pursuant to Rule 457(g) under the Securities Act. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), the registrant is also registering an indeterminate number of additional shares of Common Stock that may become issuable as a result of any stock dividend, stock split, recapitalization or other similar transaction, and the shares of Common Stock set forth in this table shall be adjusted to include such shares, as applicable. Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(o) under the Securities Act. The proposed maximum aggregate offering price of the common stock will be reduced on a dollar-for-dollar basis based on the offering price of any pre-funded warrants issued in the offering, and the proposed maximum aggregate offering price of the pre-funded warrants to be issued in the offering will be reduced on a dollar-for-dollar basis based on the offering price of any common stock issued in the offering. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), the registrant is also registering an indeterminate number of additional shares of Common Stock that may become issuable as a result of any stock dividend, stock split, recapitalization or other similar transaction, and the shares of Common Stock set forth in this table shall be adjusted to include such shares, as applicable. Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(o) under the Securities Act. No separate fee is required pursuant to Rule 457(g) under the Securities Act. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), the registrant is also registering an indeterminate number of additional shares of Common Stock that may become issuable as a result of any stock dividend, stock split, recapitalization or other similar transaction, and the shares of Common Stock set forth in this table shall be adjusted to include such shares, as applicable. Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(o) under the Securities Act. In addition to the common stock set forth in this table, pursuant to Rule 416 under the Securities Act, this registration statement also registers such indeterminate number of common stock as may become issuable upon exercise of the pre-funded warrants and common stock purchase warrants. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), the registrant is also registering an indeterminate number of additional shares of Common Stock that may become issuable as a result of any stock dividend, stock split, recapitalization or other similar transaction, and the shares of Common Stock set forth in this table shall be adjusted to include such shares, as applicable. Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(o) under the Securities Act. No separate fee is required pursuant to Rule 457(g) under the Securities Act. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), the registrant is also registering an indeterminate number of additional shares of Common Stock that may become issuable as a result of any stock dividend, stock split, recapitalization or other similar transaction, and the shares of Common Stock set forth in this table shall be adjusted to include such shares, as applicable. Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(o) under the Securities Act. Represents warrants to purchase an amount of shares of our common stock equal to 3% of the number of shares of common stock and/or pre-funded warrants and/or common stock purchase warrants issued in this offering (including any shares sold to cover over-allotments, if any), at an exercise price per share equal to 120% of the public offering price).